Friday, 29 October, is World Stroke Day, an annual observance by the World Stroke Organization. Stroke affects one in four people in their lifetime and one third of all cases end in the death of the patient. At the same time, stroke is the most common cause of permanent disability. Stroke can be recognised by three symptoms. Quick medical intervention can save a patient’s life and lead to a full recovery. That’s why on October 29, the Public Health Group of the Cerebrovascular Research Program at International Clinical Research Center at St. Anne’s University Hospital (FNUSA-ICRC) is preparing a live broadcast to spread stroke awareness.

Stroke affects more Czechs annually than heart attacks. The latter affects around 22,000 people each year, while stroke affects around 25,000 per year. Although the average age of a stroke patient is around 70, the number of younger patients is increasing worldwide.

One of the young patients treated after a stroke attack at St. Anne’s University Hospital (FNUSA) is Eliška Nováková. She suffered a stroke at the age of 20. “I had a stroke in the morning, but we didn’t call an ambulance until the afternoon and I was taken to the operating room at six in the evening. The doctors told my parents that it was a miracle that they saved me. I forgot to speak and took my first steps only after a few weeks in hospital,” she says of her experience. Today, eight years later, she still practises her speech and mobility daily. She shares her story with others through the blog „Girl with a Disability“. (https://www.holkashandicapem.cz/)

Like Eliska, many people underestimate the symptoms of a stroke. That’s why they come to the care of doctors too late. The consequence is a high rate of death and permanent disability. “The most common symptoms of stroke include limited mobility or paralysis of the limbs on one side of the body, drooping of the corner of the mouth and unintelligible or confused speech,” lists prof. MUDr. Robert Mikulík, Ph.D., who is the head of the Cerebrovascular Research Team of the FNUSA-ICRC.

Time plays the most important role in stroke treatment. Every minute, a patient loses two million neurons, so it is essential to immediately call the emergency services on 155 when recognizing at least one of the symptoms described above. “Treatment should ideally be started within an hour of the onset of symptoms. The later the patient gets to medical care, the more the chances of a cure decrease,” explains prof. Mikulík.

Rapper MC Gey also raps about stroke in a new awareness video. He drew on his own experience when writing the lyrics – two of his loved ones have survived strokes, but each with differently severe consequences. The clip, aptly titled Corner, will premiere live on a Facebook event called World Stroke Day, which kicks off at 2pm on Friday. In addition to the new video clip, those interested can look forward to an online program full of information and tips. The online event will include an interview with Eliška Nováková, information about risk factors, prevention, and what happens to a patient after being transported by ambulance to the hospital. The virtual guided tour will be conducted by prof. Robert Mikulík.

MCGEY

 

 

 

 

 

Saste Roma – Improving Health in Excluded Localities project is funded by EEA Grants 2014-2021, project no. ZD-ZDOVA2-002.ILN logo

MUDr. Zdeněk Stárek, Ph.D. from the St. Anne’s University Hospital in Brno has won the Jesenius Award, which is intended for doctors who have made the greatest contribution to the progress in medicine. The winners of the Jesenius Prize are nominated by professional and interest organizations, and a specific person is selected by a committee of experts under the auspices of the Patients’ Union.

Zdeněk Stárek is the head of the electrophysiology department at the First Internal Cardiac Angiology Clinic of St. Anne’s University Hospital in Brno and the Faculty of Medicine of the Medical University of Brno, as well as the head of the Interventional Cardiac Electrophysiology research team of the International Clinical Research Centre of the FNUSA. “I appreciate the award very much, but it is the result of cooperation of the entire research team and other partners, so I see it as a team award,” said MUDr. Stárek. Director of St. Anne’s University Hospital in Brno Ing. Vlastimil Vajdák added: “Of course, I am happy for every award for the excellent work of our experts. It is all the more important when success in the field of science comes together, which in turn translates into successful treatment of patients. This is a concrete example of how beneficial the connection between a hospital and a science centre is. Congratulations to Dr. Stárek.”

Zdeněk Stárek received the award in particular for his contribution to the Czech patent and utility model of the alternating electroporation generator, which is a non-thermal energy source that enables ablation of the heart muscle during catheter treatment. The new solution will particularly help patients with cardiac arrhythmias and in earlier diagnosis of several types of cancer. Thermal radiofrequency energy is currently used as a standard treatment for cardiac arrhythmias, i.e. ablation (literally stripping) of abnormal heart tissue, but it can damage surrounding structures such as the oesophagus. The Czech patent is registered together with the Brno University of Technology.

The Doctor of the Year poll has long-standing auspices of the Czech Medical Society J. E. Purkyně. This year it was held for the thirteenth time.

Zdenek-Starek

The International Clinical Research Centre at St. Anne’s University Hospital in Brno will have a new director from January 2022. Prof. MUDr. Irena Rektorova, Ph.D., was selected on the basis of a selection procedure.

Prof. MUDr. Irena Rektorová, Ph.D., a prominent Czech neurologist and scientist, is currently working as a research group leader at the Central European Institute of Technology CEITEC of Masaryk University and as a neurologist at the First Neurological Clinic of St. Anne’s University Hospital in Brno. She will take up the position of Director of FNUSA-ICRC in the new year 2022.

This year, the International Clinical Research Centre (FNUSA-ICRC) will conclude one of the most challenging chapters in its history, namely a demanding restructuring. It was with this task in mind that interim director Pavel Ivanyi, MBA, LL.M., took up his post a year and a half ago. “I am pleased to have been able to contribute to the successful ‘anchoring’ of the Centre at a time when we have had to make a number of changes due to reduced funding. The time has now come when we need a scientist with the skills of a manager to lead the whole institute and take this great institution forward,” said Pavel Ivanyi.

Professor Irena Rektorova is looking forward to her new position, and so far she has only commented briefly: “This is a very demanding challenge, and my clear priority will be excellent research.”

The director of St. Anne’s University Hospital in Brno, Ing. Vlastimil Vajdak added: “Prof. Irena Rektorova is a great expert, well-known in the field of neuroscience not only in the Czech Republic. I consider her future engagement in our International Clinical Research Centre to be an excellent choice and I believe that under her leadership the research teams will achieve even more significant results.”

Irena-Rektorova

The sixth annual conference Cannabis and Science was held at the Brno Observatory and Planetarium. The purpose of the event is to evaluate the development of research and treatment with cannabis, education and news in this field. The conference was attended by 160 people from the ranks of doctors, biologists, researchers, scientists, students and patients.

Due to epidemiological conditions, one of the main speakers, Lumír Hanuš, a Czech chemist and scientist living in Israel. Despite this, the conference had a very busy programme. “On the agenda were topics ranging from basic research, i.e. the study of genetics, through the plant itself, cultivation, processing, the creation of medicinal preparations to clinical trials in our country and in the world. In the afternoon part, there was also experience from the perspective of doctors and patients,” said MVDr. Václav Trojan, Head of the Clinical Pharmacology Unit of the International Clinical Research Centre at St. Anne’s University Hospital in Brno (FNUSA-ICRC).

The conference originally started as an event of several enthusiasts who were involved in cannabis research. Now it has international participation, including professors from different disciplines. All agree that cannabis has a future. “Thanks to the changes that are taking place in the Czech legislation regarding cannabis, we are on the threshold of a period when we will move perhaps more steps in this area than in the past. This will help us to further intensify the connection between research and patients,” said FNUSA-ICRC Director Pavel Iványi.

St. Anne’s University Hospital in Brno is a leader in cannabis treatment in the Czech Republic. “We are currently treating 240 patients with cannabis for chronic pain of various origins, up from 220 last year. The biggest increase was recorded at the beginning of 2020, when it was decided that 90 percent of the prescribed medical cannabis would be covered by health insurance. Until then, there were only dozens of patients,” added the head of the FNUSA Pain Management Centre, Radovan Hřib, MD, who is also involved in cannabis research at the FNUSA International Clinical Research Centre.

“In the last two years we have achieved many things, such as the establishment of the Cannabis Research Centre or the commissioning of a cannabis cultivation facility for research. I am delighted to be part of a journey that starts with genetic information and ends with the patient. I am proud and grateful that we can develop something like this in this combination and I dare say we are the only ones in the world. At St. Anne’s University Hospital in Brno we have scientists, doctors and patients in one place, which is really unique,” added Václav Trojan.

cannabis and science

October is the last month of the MSCA IF Mobility Support Project at FNUSA-ICRC. Its main objective was to support the professional development of our centre’s researchers and thus indirectly promote quality research and scientific collaboration at the FNUSA-ICRC. The project enabled two excellent scientists to join our centre’s research teams and their research activities.

Marco De Zuani, Ph.D. MSc. worked in the Cellular and Molecular Immunoregulation team under the supervision of Mgr. Jan Fric, Ph.D. He was mainly involved in research on stem cell behavior during sepsis. He focused on research on myeloid-derived suppressor cells (MDSC), which are a diverse population of cells that negatively influence the immune response during inflammation, infections, transplantation and cancer.

The role of these cells during sepsis, i.e. in layman’s terms blood poisoning, was described in the paper “Human myeloid-derived suppressor cell expansion during sepsis is revealed by unsupervised clustering of flow cytometric data” in the European Journal of Immunology (IF 5,18), with Marco de Zuani being the first author of this study. “The data from this study suggest that the abundance of these cells could be associated with the increased mortality observed in patients who survived septic shock,” Dr. De Zuani said. Thus, targeted therapy aimed at MDSC cells could improve the prospects of sepsis patients for their overall recovery.

Dmitrii Nikitin, Ph.D., CSc. D., has been involved in research at the Loschmidt Laboratories of the Faculty of Science of MU and FNUSA-ICRC. He focused mainly on the development of new thrombolytics in close collaboration with the Stroke research team. Effective treatment in stroke depends on rapid thrombus dissolution and minimizing damage to surrounding tissues. Thrombolytic agents are key players in these therapies. Dr. Nikitin’s research has focused, among other things, on staphylokinases, an enzyme produced by staphylococcal bacteria, and their use in dissolving thrombi. Better thrombolytic properties may thus lead to lower therapeutic doses and a lower risk of bleeding complications. The research results could thus help save lives and heal many patients in the future.

Supported by the European Regional Development Fund – Project Support of MSCA IF fellowships at FNUSA-ICRC (No CZ.02.2.69/0.0/0.0/19_074/0016274)

Cardiovascular magnetic resonance imaging is one of the most advanced non-invasive methods of obtaining information about the heart and its function. One of the methods used is T1 mapping, which allows to measure the extracellular (interstitial) volume of the heart muscle, as one of the important markers of cardiovascular diseases.

T1 mapping uses measured T1 relaxation time values obtained before and after administration of a gadolinium contrast agent. However, the hematocrit value, which is the proportion of red blood cells to total blood volume, is also important for accurate calculation. In the study, researchers from the Cardiovascular Magnetic Resonance team at the International Clinical Research Centre at St. Anne’s University Hospital Brno and the I. IKAK of St. Anne’s University Hospital Brno focused on determining it using values obtained directly during T1 mapping. This method greatly simplifies the whole procedure and is already used in some centres, but a comprehensive overview of calculation methods has not been published yet. In addition to determining the best method of calculation, the researchers also attempted to further refine the formula by adding the values obtained after the application of the contrast agent.

For this purpose, they used values obtained by measuring 139 patients. “We first measured hematocrit values using standard laboratory techniques, then used cardiovascular magnetic resonance to determine the T1 relaxation times of the blood before and after contrast agent administration and used statistical methods to determine the relationship between these values. Subsequently, we investigated the accuracy of the calculation with each type of formula using conventional formulas, calibrated statistically for our department and then adding post-contrast values,” said Dr. Lukáš Opatřil.

In the end, the reciprocal model of the formula calibrated for the workplace proved to be the most accurate and the addition of post-contrast values further improved its accuracy significantly. “Using this calculation could unify and refine this time- and cost-efficient method in the future,” said Dr Opatřil.

The final formula and the full study can be found here:

OpatrilCMR measurement

The Large Research Infrastructure CZECRIN was created based on close cooperation between Masaryk University, and the International Clinical Research Centre of the University Hospital at St. Anny in Brno passed the international evaluation of research infrastructures with the total number of points.

The Large Research Infrastructure CZECRIN, which supports academic clinical trials and connects university hospitals, universities, and research centers in the field of biomedicine, has achieved an excellent evaluation in the last international evaluation of research infrastructures in the Czech Republic, announced and coordinated by the Ministry of Education. CZECRIN thus received recommendations for financing in the coming years. “We are particularly pleased that we have defended the highest possible evaluation from the previous 2018 evaluations. Since then, we have not only maintained a high level of infrastructure but have also significantly developed its activities,” adds Lenka Součková, national infrastructure coordinator and assistant professor at the Institute of Pharmacology, Faculty of Medicine, Masaryk University.

Since the last evaluation, after which the infrastructure also became a full member of the European ECRIN network (status valid since 2018), CZECRIN has expanded its expertise, thus expanding the areas of support for medical facilities and research. CZECRIN offers its members comprehensive support in the field of clinical research in all its phases. An All-In-One scheme provides researchers with consultation, management, and coordination of clinical trials, regulatory expertise, pharmacoeconomic studies and offers research access to a unique certified GMP unit for research and development of advanced therapy medicinal products (ATMP).

The infrastructure has also given rise to industry-oriented networks to facilitate cooperation in individual research areas (e.g., STROCZECH – Czech Stroke Research Network, CZECRIN ONCO) and is constantly expanding its reach and support. “It is a unique connection between researchers-physicians and the already existing research network, which helps them to implement their ideas for the implementation of academic clinical studies. Industry-oriented networks reflect leading research areas in medicine, and thanks to involvement in CZECRIN, it is possible to verify directly and subsequently apply innovations to patient care.” explains doc. MUDr. Regina Demlova, Ph.D., director of Infrastructure and Head of the Institute of Pharmacology, Faculty of Medicine, Masaryk University.

This year, CZECRIN is part of 92 national and 22 international projects focused on clinical research to optimize human health care.

The second highest civilian award, the Order of the Italian Star, was awarded to an Italian scientist Giancarlo Forte this June. He received the award in recognition of his work and for representing Italy abroad. He is the head of the Center for Translational Medicine at the International Center for Clinical Research of the St. Anne’s University Hospital in Brno (FNUSA-ICRC), which he has built and has been working there for more than 8 years. In the past, he also lived and worked in Japan and Germany, but since 2013 he has been living with his wife in Brno, where their daughter was born in 2017.

When it comes to his research, he studies cardiovascular diseases, diseases of the brain and nervous system, immune system diseases and selected types of cancer. As a part of his research, he also works with stem cells that can regenerate tissues and thus represent a potential for the treatment of many diseases.

award-forte

Was becoming a scientist always your dream, or did you have another career in mind?

When I was a kid, I wanted to become an archeologist. Because I had this dream of becoming Indiana Jones, but then with time, I developed an interest in natural sciences and biology. My decision to become a scientist was made in high school.

Previously you worked and lived abroad, why did you choose specifically Germany and Japan?

Usually, in science, you don’t choose that much as far as location is concerned because of the projects. Whenever you are working on a specific scientific project, you make sure that you choose the best place where this can be pursued. So Germany came as an offer after my Graduation, and I was interested in the offered project. So I decided to move there. With Japan, it was similar, but in that case, one of my mentors of the Ph.D. moved to japan, and he invited me to join for a while. During that period, I met a japanese professor who invited me to apply for a position, and that’s how I got the job in Japan. Moving around is basically driven by science and the specific programs that each place focuses on.

Were you always planning to work or live abroad?

No, I always had this idea of being a globetrotter, and I wanted to actually move abroad for a period of time. I just didn’t know how long this period would be. And then with science, you are told constantly that you should go to the best lab or to follow the project you are working on. And then it became natural. It’s kind of a natural part of the life of all scientists.

Out of all the places in the world, why did you choose Brno?

This was pure chance. Basically, after a few years in Japan, I decided I wanted to go back to Europe because of the earthquake, nuclear fallout, and tsunami. Those are the moments when you realize how far you are from Home. I started to look for a position, and then I found a possible position in this brand-new institute in Brno, and I simply took the challenge. I visited Brno, and I liked it immediately, so together with my wife, we decided that it was a good place to start fresh.

How different is Brno from other places where you have worked? Or is it the same everywhere?

No, it’s not the same everywhere. It’s completely the opposite of Japan. Since being in Japan feels like living upside down, Brno feels like going back to normality. European lifestyle is somehow homogenous, more homogenous than living in the far east or in the USA, so Brno is very close to our lifestyle. I think I just experienced the language shock, I was quite used to the European lifestyle, and Brno is quite a European city.

Is there something in Italy you miss now that you live in Brno?

We miss our family and friends. When you move around, you somehow feel closer to long-term friends. As we travel and move abroad, we are actually driven to value friendship and family more. Apart from that I also miss the weather and the food, but that’s something you can live with.

What does the award mean for those who receive it? And What does it mean to you specifically?

The award is a commendation by the president of the Italian republic, which is given to Italians but sometimes also foreigners who help represent the nation abroad. Even Though it is an old status, I was happy to see that probably for the first time, it was awarded to a scientist. Usually, most young italian scientists are forced to go abroad because there are no possibilities to work at home. I don’t think it’s bad, I decided to go on my own, and I never felt exiled. But for all Italian scientists who are abroad, it’s nice to hear that the president values our contribution even though we are not giving it directly to the country, but we are giving it to the country from abroad. So in my case, I felt that it was an appreciation of the work we have been doing. And it’s not just about me. It’s about the whole lab and the whole FNUSA-ICRC and what we have been doing to create an international environment and to make all the students and scientists who are traveling the world feel comfortable and like they are at home. We have many nationalities in the lab, and people are, as far as I know, happy to be there. We give them a chance, train them, and make sure they feel welcome.

award-forte2

What does your research focus on?

I specifically coordinate the center for translational medicine within the FNUSA-ICRC, where we do translational research. So we study and investigate the molecular basis of diseases affecting the cardiovascular system, diseases of the nervous system (brain and nervous system), diseases of the immune system, and some selected kinds of cancer. We basically try to bridge the clinical experience of the pathology itself, of the symptoms with the causes at the cell and tissue level.

What are your research plans or goals for the future, and are you planning to stay in Brno?

During these years, we have made some interesting contributions and discoveries about new possible mechanisms of pathologies both in cancer and in cardiovascular diseases, so we would like to investigate this further. The challenge here is to turn our knowledge of the mechanisms of disease into a cure. We would be happy to move a little closer to the clinics and the patients and try to understand how we can control these molecular processes to design some potential treatments. Obviously, I am dreaming here because the path to the clinics is very far for everybody, and it is clear to everybody that the path from translational science to the design of disease treatment is a very long one.

When it comes to moving abroad, that depends on many circumstances. It’s also true that scientists are globetrotters, and sooner or later, they need to find a new place. It’s possible that in the future, we will look for new challenges somewhere else, but for the time being, we are happy in Brno. We are happy with the possibilities we have to do research and express ourselves as scientists, and there is currently no plan we have for the far future.

Do you have any wild dreams or plans you have when it comes to research?

Most of the science is incremental. We try to take little steps in one direction, which are fueled not only by curiosity but also by the support of other colleagues. This knowledge builds up, and then, in the end, you reach something revolutionary, but most of the efforts are incremental. I definitely don’t plan a revolution. Revolutions in science are usually random, so they come just by chance.

award-forte3

Protein Engineering team at International Clinical Research Center of St. Anne’s University Hospital Brno (FNUSA-ICRC) and Faculty of Science of Masaryk University has focused on the potential of web-based screening tools in accelerating the discovery of cancer-treating drugs based on microbial products. Protein Engineering team have presented a review of web screening tools, such as molecular databases, and provided a step-by-step description of how to use them. “Our goal is to increase awareness of available virtual screening tools within the medical and scientific community, particularly among those working in experimental and clinical oncology,” explained head of the team Jiří Damborský. There are multiple methods and the use of each depends on the available information we have about the microbial products and the molecules being targeted.

At the moment, cancer can be treated by chemo, radiotherapy, surgery, RNA-binding proteins, targeted therapy, or immunotherapy which uses microbial products. Microbial products, such as cellular components or viral particles, are used to target and inhibit proteins involved in carcinogenesis and present a relatively low-cost method to treat cancer. However, there are many different microbial products that could be used and many different proteins that need to be targeted. That is why virtual screening tools are essential in making the process of finding potential anti-cancer drugs more efficient, as they predict how specific molecules will react with one another and thus show us which combinations are most promising.

Overall, the use of virtual screening tools presents an available and low-cost way to speed up the discovery and development of anti-cancer drugs while also enriching the online databases of compounds that could be tested in the future. “However, it is essential to keep in mind that using automated web tools brings challenges of its own, and, for most computational methods, the results will only be as good as the input data,” concluded the head of Bioinformatics unit David Bednář.

The full review is available here

David-Bednar

The blood of many animals, including humans, contains about 40% red blood cells, which bind oxygen but also impede blood flow in the blood vessels. Mathematical models suggest that 40% is optimal. It provides the highest oxygen supply to the tissues. Nature has arrived at it through evolution. However, previous theories have not explained why elite athletes perform better after (illegal) blood transfusions or erythropoietin, nor why there are animals, such as dogs and horses, that expel concentrated blood from the spleen during physical exercise. In both cases the resulting haematocrit is higher than the optimal 40%.

“Together with Dr. Stark and Prof. Schuster from the Friedrich Schiller University in Jena, Germany, we studied the optimal percentage of red blood cells in the blood (the so-called hematocrit) during extreme physical exertion limited by cardiac performance,” said Michal Šitina, M.D., head of the Biostatistics research team at the International Clinical Research Centre of St. Anne’s University Hospital in Brno.

“In our study, we mathematically described the blood oxygen supply to tissues both under resting conditions without cardiac restriction and under conditions of extreme physical exercise, when blood flow is restricted by maximal cardiac output,” described Šitina. The calculation showed that under resting conditions, the optimal hematocrit value is indeed 40%, but it rises to 60% during physical exercise. This is the value observed in horses just after a race. This work thus explained the observed findings and refined the theory of the optimal haematocrit. Limiting cardiac performance, however, even without major physical exertion, are patients with severe heart failure. “In the next theoretical study, we would like to calculate the optimal hematocrit value for just such patients,” said Šitina

The article is available here:

Michal-Šitina